Page 26 - MemoriaSAM-Eng

SCIENTIFIC PROGRAMMES

Schizophrenia

Programme Serious mental disorders, particularly schizophrenia, are a priority line of research in
the World Health Organization and the European Economic Community. The Schizo-
Description
phrenia Programme involves the largest number of groups (12). This programme has a

very extensive clinical, genetic and neuroimaging database in the different CIBERSAM
platforms. Important collaborative projects relating to the progression of first psy-

chotic episodes have been developed through this programme.

• To increase the number of samples from patients diagnosed with schizophrenia
Objectives
sent to the different platforms: DNA, Brain Bank, Neuroimaging, GRIDSAM.

• To study the genetic, neurophysiological, neuroimaging (structural, neurochemi-

cal and functional) and biochemical variables in the initial stages of psychosis.

• To study the neurobiological (genetics, neuroimaging and neurophysiological)

basis of the different symptomatological phenotypes of schizophrenia.

• To study the clinical and neurobiological response phenotypes (neuroimaging,

neurophysiological and cognitive) to different pharmacological treatments.

•
To conduct research on the efficacy and effectiveness of psychotherapeutic
treatments in combination with standard pharmacological treatments in schizo-

phrenia.

•
To study the repercussions of schizophrenia on the state of health, psychosocial

adjustment, quality of life, the individual’s levels of disability and on patient ser-
vice use patterns and the effect on comorbidity.

13
0
2
RT
O
EP
R
AL
U
NN
A
/
M
SA
R
BE
CI

26